Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of MORAb-004 in Patients With Solid Tumor

Trial Profile

A Phase 1 Study of MORAb-004 in Patients With Solid Tumor

Phase of Trial: Phase I

Latest Information Update: 09 Jan 2019

At a glance

  • Drugs Ontuxizumab (Primary)
  • Indications Chondrosarcoma; Gastric cancer; Gastrointestinal stromal tumours; Liver cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 09 Jan 2019 Results published in the Investigational New Drugs
    • 08 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 19 Jan 2016 Planned End Date changed from 1 Jun 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top